

Hydra Biosciences Appoints Glenn R. Larsen, Ph.D. as Chief Scientific Officer

Former Wyeth Executive to Lead Hydra Research and Development

CAMBRIDGE, MA — December 4, 2003 — Hydra Biosciences, Inc., a biopharmaceuticals company pioneering the discovery of molecular regeneration medicines, today announced the appointment of Glenn R. Larsen, Ph.D., as Chief Scientific Officer, Executive Vice President, Research and Development. Dr. Larsen will also become a member of Hydra's Board of Directors. He joins Hydra from Wyeth Pharmaceuticals, where he served as Vice President, Musculoskeletal Sciences, directing R&D for Wyeth's second largest therapeutic area in the fields of arthritis, inflammation and tissue regeneration. Dr. Larsen also co-chaired the Musculoskeletal Therapeutic Area, responsible for directing Wyeth's global commercial and development efforts for: Enbrel™, an anti-TNF agent for rheumatoid arthritis, with sales in excess of \$1 billion; Synvisc™, for osteoarthritis; and BMP-2, a bone regenerating factor.

Hydra is pioneering the exciting new field of regeneration biology with molecular medicines that have the potential to revolutionize the treatment of many diseases. The Company is applying its technology toward the discovery of proteins and small molecule drugs that reprogram a patient's own cells to restore damaged or injured tissue without scarring. Hydra's planned molecular regeneration medicines will provide important clinical and commercial advantages over cell-based therapies. The Company's molecular approach to the promise of regeneration medicine can be applied to multiple disease areas including heart, vasculature, muscle, retina, kidney, central nervous system, pancreas, skin and joints, among others. The Company's core molecular regeneration program, with an initial focus on cardiac regeneration, is complemented by programs in novel vascular therapeutics and drugs targeting ion channels.

Hydra successfully completed a \$9.3 million Series A financing in 2002 led by Polaris Ventures, with Abingworth as co-lead and Advanced Technology Ventures, Boston Medical Investors and New Enterprise Associates also investing. In connection with two multi-year, revenue-generating research collaborations signed with Abbott Laboratories in 2002, Abbott made a non-controlling equity investment in Hydra.

"Glenn's impressive combination of scientific expertise and business acumen will be an invaluable asset to Hydra Biosciences. His successful track record in drug discovery, product development, and advancing candidates through the clinic, make him a key addition to Hydra's management team," stated Mr. Matthew Gantz, President and Chief Executive Officer, Hydra Biosciences, Inc. "Glenn's more than 20 years of experience advancing both biologics and small molecules make him an ideal leader of Hydra's research and development programs."

Prior to Wyeth's acquisition of American Home Products - Genetics Institute, Dr. Larsen served as Vice President, Preclinical Research and Development at Genetics Institute. Dr. Larsen began his career with Genetics Institute, a biopharmaceutical company, where he held a variety of leadership positions in drug discovery, program management and drug development. Dr. Larsen received his Ph.D. in Biochemistry from the State University of New York at Stony Brook and is a graduate of Harvard University's Business School PMD program.